Casdin Partners Master Fund, L Acquires 450,000 Shares of Standard BioTools (NASDAQ:LAB) Stock

Posted by Alphonse Anthony on Nov 19th, 2025

Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) Director Casdin Partners Master Fund, L purchased 450,000 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was acquired at an average price of $1.20 per share, for a total transaction of $540,000.00. Following the acquisition, the director owned 62,500,000 shares in the company, valued at $75,000,000. This trade represents a 0.73% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

On Monday, November 17th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.22 per share, for a total transaction of $274,500.00.
On Friday, November 14th, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.24 per share, for a total transaction of $310,000.00.
On Wednesday, November 12th, Casdin Partners Master Fund, L bought 375,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.19 per share, with a total value of $446,250.00.
On Tuesday, November 11th, Casdin Partners Master Fund, L purchased 300,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $360,000.00.
On Monday, November 10th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.17 per share, for a total transaction of $321,750.00.
On Friday, November 7th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.12 per share, with a total value of $252,000.00.
On Tuesday, September 9th, Casdin Partners Master Fund, L bought 100,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.29 per share, for a total transaction of $129,000.00.
On Wednesday, September 3rd, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.27 per share, for a total transaction of $317,500.00.
On Tuesday, August 26th, Casdin Partners Master Fund, L purchased 125,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.26 per share, with a total value of $157,500.00.
On Monday, August 25th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.24 per share, for a total transaction of $248,000.00.

Standard BioTools Price Performance

Shares of NASDAQ LAB opened at $1.24 on Wednesday. The stock has a market capitalization of $476.86 million, a price-to-earnings ratio of -3.88 and a beta of 1.25. The firm’s 50 day simple moving average is $1.28 and its 200-day simple moving average is $1.23. Standard BioTools Inc. has a 12 month low of $0.92 and a 12 month high of $2.25.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Cowen cut shares of Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. TD Cowen lowered their target price on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $1.35.

Read Our Latest Stock Report on LAB

Institutional Trading of Standard BioTools

Institutional investors have recently modified their holdings of the stock. Jump Financial LLC acquired a new position in shares of Standard BioTools during the 1st quarter worth about $26,000. Russell Investments Group Ltd. increased its stake in Standard BioTools by 2,989.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock worth $33,000 after buying an additional 24,211 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Standard BioTools by 115.6% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after acquiring an additional 14,541 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of Standard BioTools by 103.6% during the third quarter. Federated Hermes Inc. now owns 28,545 shares of the company’s stock valued at $37,000 after acquiring an additional 14,523 shares during the last quarter. Finally, CWM LLC lifted its position in shares of Standard BioTools by 101.8% in the first quarter. CWM LLC now owns 29,705 shares of the company’s stock valued at $32,000 after acquiring an additional 14,984 shares in the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

About Standard BioTools

(Get Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.